PR Newswire
LONDON, March 3, 2026
The new report «Hematologic Malignancies Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast 2024-2032» has been added to the library of Credence Research Inc.
LONDON, March 3, 2026 /PRNewswire/ — The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032, registering a CAGR of 7.47% during 2024-2032.
https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg
Growth is underpinned by the rising incidence of blood cancers (leukemia, lymphoma, and myeloma), increasing adoption of targeted and immune-based therapies, and greater emphasis on early detection and precision medicine. An expanding geriatric population, which faces a higher risk of hematologic cancers, further enlarges the addressable patient pool. At the same time, developers are advancing immunotherapies, gene therapies, and CAR-T cell therapies, improving clinical outcomes and supporting revenue expansion.
Pharmaceutical manufacturers, research institutions, and healthcare providers are accelerating innovation through collaborations, higher oncology R&D spending, and supportive regulatory approvals, which together are expected to sustain market momentum over the forecast period.
Request your sample report today and start making informed decisions powered by Credence Research Inc.
Download Sample – https://www.credenceresearch.com/report/hematologic-malignancies-market
Rising Prevalence of Hematologic Malignancies
The increasing incidence of leukemia, lymphoma, and multiple myeloma is a fundamental growth driver. Greater awareness among patients and clinicians is leading to more frequent diagnostic testing, supporting earlier detection and treatment initiation. Population aging in both developed and emerging markets is expected to further elevate disease prevalence, expanding the number of patients eligible for therapy across first-line, relapsed, and refractory settings. This growing burden is pushing drug developers to pursue novel mechanisms and more durable treatment approaches designed to improve survival and quality of life.
Advancements in Targeted Therapies and Precision Medicine
Advances in targeted therapies, immunotherapies, and precision medicine are reshaping the standard of care in hematologic malignancies. Approaches such as CAR-T cell therapy, gene therapies, and pathway-specific inhibitors offer the potential for improved efficacy and reduced toxicity compared with conventional chemotherapy in defined patient subsets. Products like Novartis’ Kymriah helped validate CAR-T as a commercially viable option in select blood cancers and underscored the potential of personalized cellular therapies. As clinicians increasingly match treatment to patients’ genetic and molecular profiles, pharmaceutical companies gain new opportunities to develop differentiated pipelines and capture share in high-value niches.
Shift Toward Immunotherapies and CAR-T Cell Treatments
Immunotherapies and CAR-T cell treatments are emerging as a central trend within the hematologic malignancies landscape. These modalities harness the patient’s immune system to selectively target malignant cells and can offer deep and durable responses in certain relapsed or refractory settings. CAR-T therapies have already demonstrated strong efficacy in specific leukemias and lymphomas and are expanding into multiple myeloma and additional hematologic indications. For instance, Novartis Pharmaceuticals’ PHE885, a BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma, uses the T-Charge platform to improve T-cell persistence and shorten manufacturing time, potentially enhancing both outcomes and operational feasibility.
Increasing Use of Biomarker-Driven Therapies
The use of biomarker-driven therapies is becoming more widespread as clinicians increasingly rely on genetic mutations and molecular markers to guide treatment selection. By matching therapies to specific disease characteristics such as particular gene fusions, pathway alterations, or surface antigens providers can improve efficacy while reducing unnecessary toxicity. Broader deployment of biomarker testing and more accessible molecular diagnostics is enabling more nuanced treatment algorithms that are expected to significantly shape care pathways over the coming years.
High Treatment Costs and Access Constraints
The high cost of advanced therapies–including CAR-T treatments, targeted immunotherapies, and complex combination regimens–remains a significant barrier to widespread adoption. Total cost of care often includes hospitalization, specialized facilities, and intensive monitoring in addition to the drug itself. For example, Gilead Sciences’ Yescarta has a list price in the hundreds of thousands of dollars per patient, underlining affordability challenges. In many low- and middle-income countries, limited reimbursement and constrained oncology infrastructure further restrict access, slowing uptake despite strong clinical benefits.
The Hematologic Malignancies Market presents substantial opportunities as precision medicine, immunotherapies, and novel combination regimens expand into additional indications and earlier lines of therapy. Deeper understanding of the molecular drivers of blood cancers supports the development of targeted therapies and personalized treatment strategies, including next-generation CAR-T platforms and immune-modulating approaches.
Diagnostics represent a parallel growth avenue as health systems prioritize early detection, MRD monitoring, and treatment optimization. As the performance of liquid biopsy and NGS improves and costs decline, broader testing adoption is expected, particularly when supported by partnerships between diagnostics companies, health systems, and academic centers.
Emerging markets with improving oncology infrastructure and rising healthcare expenditure–also offer untapped potential for both therapies and advanced diagnostics, creating room for companies that can balance innovation, affordability, and access.
Market Segmentation Analysis
By Type
- Leukemia
- Lymphoma
- Myeloma
By Therapy Type
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Tyrosine kinase inhibitors
- Proteasome inhibitors
- B-cell lymphoma-2 protein inhibitors
- Isocitrate dehydrogenase-1 inhibitors
- Hedgehog pathway inhibitors
- Others
By Diagnosis
- Blood Tests
- Biopsy
- Imaging Tests
- X-ray
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Others
By Dosage Form
- Tablets
- Capsules
- Injections
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Browse Full Report –
North America is the leading regional market, accounting for around 40% of global revenue in 2024. The region benefits from high prevalence of hematologic cancers, advanced oncology infrastructure, and strong presence of global pharmaceutical and biotech companies. The U.S. drives regional growth through substantial R&D investment, leadership in CAR-T and immunotherapy development, and broad availability of advanced diagnostic tools such as NGS and liquid biopsy. Favorable reimbursement frameworks, access to cutting-edge clinical trials, and robust specialist networks further reinforce North America’s dominance.
Europe represents the second-largest regional market, with approximately 30% share in 2024. The region’s growth is supported by increasing awareness of hematologic cancers, strong public healthcare systems, and rising investment in biotechnology and pharmaceutical research. Countries such as Germany, France, and the U.K. are at the forefront of oncology innovation, with numerous ongoing clinical trials focused on novel therapies for blood cancers. Government initiatives that promote early diagnosis, improve access to innovative treatments, and support personalized medicine are further strengthening Europe’s position.
Key Player Analysis
Leading companies operating in the Hematologic Malignancies Market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Allergan (Ireland)
- Pfizer Inc. (U.S.)
- AstraZeneca (U.K.)
- Merck & Co., Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- GlaxoSmithKline plc (U.K.)
- Sanofi (France)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Mylan N.V. (U.S.)
- Eli Lilly and Company (U.S.)
Competitive Analysis
The Hematologic Malignancies Market is highly competitive, with major pharmaceutical and biotechnology companies striving to expand their presence through innovative therapies, strategic collaborations, and lifecycle management of established products. Players such as F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Merck & Co., Inc., and others are at the forefront of innovation in targeted therapy, immuno-oncology, and cellular therapies.
Common strategies include:
- Intensifying R&D investment to expand pipelines and improve efficacy and safety profiles
- Pursuing strategic partnerships, licensing deals, and acquisitions to access new platforms and assets
- Broadening indication labels and moving successful therapies into earlier treatment lines
- Enhancing patient support and access programs to improve affordability and adherence
- Strengthening diagnostics-therapeutics integration to support precision medicine approaches
The competitive environment is also shaped by regional and emerging players that focus on biosimilars, cost-effective regimens, and niche patient populations, contributing to price competition and broader access in certain markets.
Recent Developments
- January 2025 – Gilead Sciences: Announced the EU commercial launch of its next-generation CAR-T therapy Yescarta (axicabtagene ciloleucel) following regulatory clearance, expanding treatment access for relapsed/refractory large B-cell lymphoma patients.
- May 2025 – Laboratory Corporation of America (Labcorp): Launched an expanded precision oncology portfolio, adding new NGS panels for hematologic malignancies, a Rapid AML Panel, HRD testing within OmniSeq INSIGHT, and enhanced FDA-approved companion diagnostics for solid tumors.
- October 2025 – Integrated DNA Technologies (IDT) & Hamilton: Entered a strategic partnership to automate customizable NGS workflows for comprehensive genomic profiling on Hamilton liquid-handling platforms, offering platform-agnostic solutions for solid tumor and blood cancer research.
- November 2025 – Pairidex: Introduced FusionMRD, a personalized RNA-based digital PCR assay for monitoring measurable residual disease (MRD) in fusion-driven hematologic malignancies, reporting 0.001% sensitivity using peripheral blood for leukemia monitoring.
- January 2025 – BridgeBio Oncology Therapeutics (TheRas, Inc.): Reported that the U.S. FDA granted Fast Track designation to BBO-8520, an investigational oral therapy for adults with metastatic NSCLC previously treated and harboring a KRAS G12C mutation.
- February 2025 – SonALAsense: Advanced SONALA-001 (ALA-based IV agent) for sonodynamic therapy (SDT), which uses ultrasound to activate the metabolite protoporphyrin IX (PpIX), in clinical trials for adult high-grade gliomas and pediatric diffuse intrinsic pontine gliomas (DIPG)
Report Coverage
The research report on the Global Hematologic Malignancies Market provides a comprehensive and structured assessment of the industry’s evolution, competitive landscape, and long-term growth prospects from 2024 to 2032. Key elements of coverage include:
- Detailed Segmentation Analysis by:
- Type (Leukemia, Lymphoma, Myeloma)
- Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy and subclasses)
- Diagnosis (Blood Tests, Biopsy, Imaging Tests and Others)
- Dosage Form (Tablets, Capsules, Injections, Others)
- Route of Administration (Oral, Parenteral, Others)
- End-Users (Hospitals, Specialty Clinics, Homecare, Others)
- Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
- Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
- Quantitative Market Sizing and Forecasts in value terms (USD million), including historical data, base-year estimates, and forward-looking projections, with analysis of growth drivers and restraints for each major segment and region.
- In-depth Company Profiles of leading players, outlining business overviews, hematologic oncology portfolios, pipeline assets, revenue contributions, core indications, strategic initiatives, and geographic presence.
- Competitive Environment and SWOT Analysis, evaluating innovation intensity, strategic positioning, M&A and partnership activity, and the impact of emerging players and biosimilars on pricing and access.
- Market Dynamics Review, covering key drivers (e.g., rising prevalence, adoption of advanced therapies), restraints (e.g., high cost and access barriers), opportunities (e.g., precision medicine and emerging markets), and challenges (e.g., complex regulatory pathways).
- Regulatory and Policy Landscape, highlighting approval pathways, regional regulatory variations, HTA/reimbursement considerations, and how these factors influence therapy uptake and commercial strategy.
- Technology and Innovation Assessment, analyzing the role of NGS, liquid biopsy, MRD assays, CAR-T and gene therapies, bispecific antibodies, and other novel modalities in reshaping treatment pathways and commercial models.
- Macroeconomic and Healthcare System Context, examining how demographic trends, healthcare expenditure patterns, and system capacity influence market growth and access across mature and emerging regions.
- Strategic Recommendations for new entrants and established companies, including guidance on portfolio prioritization, partnering models, regional expansion, pricing and market-access strategy, and investment focus across both therapeutics and diagnostics.
Access the Complete Report – https://www.credenceresearch.com/report/hematologic-malignancies-market
Related Reports –
Checkpoint Inhibitor Refractory Cancer Market https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market
Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market https://www.credenceresearch.com/report/neoantigen-based-personalized-cancer-therapeutic-vaccines-market
Paranasal Sinus Cancer Market https://www.credenceresearch.com/report/paranasal-sinus-cancer-market
Cervical Cancer Diagnostic Market https://www.credenceresearch.com/report/cervical-cancer-diagnostic-test-market
Cancer Biological Therapy Market https://www.credenceresearch.com/report/cancer-biological-therapy-market
In Vitro Colorectal Cancer Screening Market https://www.credenceresearch.com/report/in-vitro-colorectal-cancer-screening-market
Breast Cancer Liquid Biopsy Market https://www.credenceresearch.com/report/breast-cancer-liquid-biopsy-market
Prostate Cancer Treatment Market https://www.credenceresearch.com/report/prostate-cancer-treatment-market
Thyroid Cancer Diagnostics Market https://www.credenceresearch.com/report/thyroid-cancer-diagnostics-market
Next Generation Cancer Diagnostics Market https://www.credenceresearch.com/report/next-generation-cancer-diagnostics-market
About Us
Credence Research Inc is a global market intelligence and consulting firm founded in 2015. It delivers deep market insights, quantitative analysis, and strategic guidance to business leaders, investors, governments, NGOs, and non-profit groups worldwide. The company helps organizations evaluate markets, understand trends, reduce risk, and make data-driven decisions that support growth and competitive strategy. Credence Research is known for rigorous research methods and comprehensive analytics.
The firm produces detailed reports covering market size, forecasts, growth drivers, trends, and competitive landscapes across many industries. Each report often includes frameworks like PESTLE and Porter’s Five Forces to give a complete view of market dynamics and future potential. Credence Research also provides tailored consulting services, due diligence support, go-to-market planning, and pre-IPO research to strengthen client strategies and investment narratives. Its insights come from both primary and secondary research, expert interviews, and advanced data modelling. The firm’s client base spans Europe, the Americas, Asia-Pacific, and the Middle East/Africa.
To find out more, visit www.credenceresearch.com or follow us on X.com, LinkedIn and Facebook
Contact Us -Credence Research Inc,Tower C-1105, S 25,Akash Tower,Vishal Nagar,Pimple Nilakh, Haveli,Pune – 411027, IndiaUSA: +1-888-600-6441Email: [email protected] Our Website: https://www.credenceresearch.com/
Logo: https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/hematologic-malignancies-market-to-reach-usd-128-48-billion-by-2032–driven-by-immunotherapy-car-t-and-precision-oncology–credence-research-inc-302702936.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…